Laman UtamaAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
Tutup sebelumnya
$27.32
Julat hari
$26.26 - $27.26
Julat tahun
$20.39 - $39.56
Permodalan pasaran
1.22B USD
Bilangan Purata
435.34K
Nisbah P/E
11.73
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Hasil | 191.84J | 0.33% |
Perbelanjaan pengendalian | 50.23J | 11.88% |
Pendapatan bersih | 17.35J | -57.09% |
Margin untung bersih | 9.04 | -57.24% |
Pendapatan bagi setiap syer | 0.93 | -3.12% |
EBITDA | 62.55J | -11.21% |
Kadar cukai berkesan | 19.35% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 276.21J | 10.27% |
Jumlah aset | 1.67B | 7.83% |
Jumlah liabiliti | 889.48J | 8.80% |
Jumlah ekuiti | 776.75J | — |
Syer tertunggak | 45.95J | — |
Harga kepada buku | 1.63 | — |
Pulangan pada aset | 7.38% | — |
Pulangan pada modal | 8.50% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 17.35J | -57.09% |
Tunai daripada operasi | 52.58J | -12.31% |
Tunai daripada pelaburan | -19.62J | 43.27% |
Tunai daripada pembiayaan | -4.35J | 80.95% |
Perubahan bersih dalam tunai | 28.58J | 1,044.41% |
Aliran tunai bebas | 58.63J | 133.97% |
Perihal
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Diasaskan
1996
Ibu pejabat
Tapak web
Pekerja
2,028
